(Q36310044)

13 August 2017

1 reference

title

Nebulized antibiotic therapy: the evidence (English)

1 reference

13 August 2017

0 references

S P Conway

1

1 reference

13 August 2017

publication date

1 January 2005

1 reference

Chronic Respiratory Disease

13 August 2017

published in

1 reference

13 August 2017

volume

2

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

35-41

1 reference

Aerosol therapy in cystic fibrosis

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Mists and aerosols: New studies, new thoughts

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Current understanding of the inflammatory process in cystic fibrosis: onset and etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Drug-induced ototoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Administration of aerosolized antibiotics in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Bronchoconstriction following nebulised colistin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Urinary N-acetyl-beta-D-glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Use of aerosolized antibiotics in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Compliance with treatment in adult patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1479972305CD045RS

10.1191/1479972305CD045RS

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference